P76.85 Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors
| Autor: | Padda, S. 1, Whisenant, J. 2, Neal, J. 3, York, S. 2, Iams, W. 2, Neuss, M. 2, Reckamp, K. 4, Preiss, J. 3, Berry, L. 5, Shyr, Y. 5, Wakelee, H. 1, Horn, L. 6 |
|---|---|
| Zdroj: | In Journal of Thoracic Oncology March 2021 16(3) Supplement:S626-S626 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|